Get the Stockscreener App
1,004.84
0.62%
6.20
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corp stock is traded at $1,004.84, with a volume of 618.49K.
It is up +0.62% in the last 24 hours and up +13.25% over the past month.
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$998.64
Open:
$1012.2
24h Volume:
618.49K
Relative Volume:
0.90
Market Cap:
$117.15B
Revenue:
$403.43B
Net Income/Loss:
$5.10B
P/E Ratio:
26.12
EPS:
38.4657
Net Cash Flow:
$5.41B
1W Performance:
+7.03%
1M Performance:
+13.25%
6M Performance:
+15.85%
1Y Performance:
+29.58%
1-Day Range:
$999.27
$1,014.99
1-Week Range:
$936.77
$1,014.99
52-Week Range:
$723.68
$1,014.99
Mckesson Corp Stock (MCK) Company Profile
Name
Mckesson Corp
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK vs COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corp
|
1,004.84 | 117.15B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
340.92 | 65.06B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
254.06 | 58.83B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
86.38 | 9.63B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.35 | 1.16B | 14.85M | -136.07M | 7.25M | -0.4726 |
Mckesson Corp Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-28-26 | Initiated | William Blair | Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corp Stock (MCK) Latest News
Form 144 MCKESSON CORP For: 15 October By Investing.com - Investing.com UK
An officer proposes selling 801 McKesson (MCK) shares valued at $797K. - Stock Titan
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Mckesson stock hits all-time high at 1000.97 USD - Investing.com
Jim Cramer: This Health Care Stock Is A ‘Winner’, X-Energy Is ‘Losing Too Much Money’ - Benzinga
Cramer's lightning round: 'McKesson is a winner' - CNBC
McKesson (MCK) Ascends While Market Falls: Some Facts to Note - Zacks Investment Research
McKesson (MCK) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
McKesson Corp. stock outperforms competitors on strong trading day - MarketWatch
McKesson Corporation (NYSE:MCK): What Does the Latest The Option Care Health Acquisition Agreement Change? - Kalkine Media
Operating cash flow per share of McKesson Corporation – VIE:MCK - TradingView
McKesson: Re-Rated Again Amidst Increased M&A Efforts (NYSE:MCK) - Seeking Alpha
McKesson Corp. stock outperforms competitors on strong trading day - MarketWatch
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
If You Invested $1000 in McKesson a Decade Ago, This is How Much It'd Be Worth Now - Zacks Investment Research
McKesson (MCK) Extends Key Distribution Tie Through 2032 And Expands Pharmacy Role - Simply Wall Street
McKesson Corporation (MCK) Stock forecasts - Yahoo Finance Singapore
McKesson Corp. stock outperforms competitors on strong trading day - MarketWatch
How AI Adoption Could Supercharge McKesson (MCK) - Yahoo Finance Singapore
How AI Adoption Could Supercharge McKesson (MCK) - Yahoo Finance
Here's Why McKesson (MCK) is a Strong Growth Stock - Zacks Investment Research
Here's Why McKesson (MCK) Fell More Than Broader Market - Zacks Investment Research
Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes" - Zacks Investment Research
What Is McKesson (MCK) Gaining From This $5.8 Billion Option Care Deal? - Yahoo Finance
Option Care stock surges on McKesson’s home-infusion bet - TheStreet
CD&R And McKesson To Acquire Option Care Health For $5.8 Billion - Pulse 2.0
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now? - Yahoo Finance
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now? - Zacks Investment Research
McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout - finchannel
McKesson, private equity firm buy home infusion company, Option Care Health - Managed Healthcare Executive
McKesson Just Put $32.05 Cash on America's Biggest Home Infusion Name - Money Morning
McKesson Corporation (MCK) Stock Forecasts - Yahoo Finance
Option Care Health (OPCH) Rockets as CD&R, McKesson Table 37% Premium Bid - Yahoo Finance
Why Option Care Health Stock Skyrocketed on Tuesday - The Motley Fool
McKesson, CD&R to Buy Option Care Health in $5.8 Billion Deal - Yahoo Finance
McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal - Reuters
CD&R, McKesson acquiring infusion therapy provider Option Care Health for $5.8B - Fierce Healthcare
McKesson, CD&R to buy Option Care Health for $5.8 billion - Modern Healthcare
Option Care Health Agrees to $5.8 Billion Acquisition by CD&R and McKesson at $32.05 Per Share - Yahoo Finance
McKesson Buys Home Infusion Company Option Care for $5.8B - HomeCare
McKesson, CD&R to Buy Option Care in $5.8 Billion Deal - Bloomberg.com
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CD&R, McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion - WSJ
CD&R, McKesson Corporation sign agreement to acquire Option Care Health - MLex
OPCH shares jump 34% as CD&R, McKesson agree to $5.8B takeover (OPCH:NASDAQ) - Seeking Alpha
Cd&R And Mckesson Corporation Sign Agreement To Acquire Option Care Health - TradingView
McKesson, CD&R to Buy Option Care Health in $5.8 Billion Deal - Yahoo Finance
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health - Yahoo Finance
McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports - Yahoo Finance
Mckesson Corp Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mckesson Corp Stock (MCK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rutledge Napoleon B JR | SVP, Controller & CAO |
Sep 08 '26 |
Sale |
891.45 |
111 |
98,951 |
521 |
| Lerman Bradley E | Director |
Aug 10 '26 |
Sale |
892.33 |
301 |
268,590 |
0 |
| Lerman Bradley E | Director |
Aug 10 '26 |
Proposed Sale |
892.32 |
301 |
268,589 |
0 |
| Vitalone Britt J. | Former Officer |
Aug 03 '26 |
Proposed Sale |
843.31 |
7,925 |
6,683,192 |
0 |
| TYLER BRIAN S. | Chief Executive Officer |
Jul 07 '26 |
Sale |
793.56 |
8,463 |
6,715,898 |
5,919 |
| TYLER BRIAN S. | Officer |
Jul 07 '26 |
Proposed Sale |
793.56 |
8,463 |
6,715,898 |
0 |
| TYLER BRIAN S. | Officer |
Jun 17 '26 |
Proposed Sale |
775.13 |
8,463 |
6,559,925 |
0 |
| TYLER BRIAN S. | Chief Executive Officer |
Jun 17 '26 |
Sale |
775.13 |
8,463 |
6,559,925 |
14,382 |
| TYLER BRIAN S. | Officer |
Jun 09 '26 |
Proposed Sale |
763.00 |
4,929 |
3,760,827 |
0 |
| TYLER BRIAN S. | Chief Executive Officer |
Jun 09 '26 |
Sale |
763.00 |
4,929 |
3,760,827 |
22,845 |
0.14%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):